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The authors aimed to evaluate the safety and immunogenicity of a live attenuated SA14-14-2 Japanese Encephalitis 
(JE) vaccine in healthy Thai infants. One hundred and fifty subjects aged9-15 months were vaccinated with one dose of this 
vaccine. Regarding the vaccine safety, during the 28-day post-vaccination follow-up, no vaccine-related serious adverse 
events were reported. In terms of immunogenicity, the sero-conversion rate of a single dose vaccination was 95% (95%} CI, 
90.0-97.6%)) within 90 days after vaccination and the geometric mean titer (GMT) was 66.1. Eight subjects with JE sero-
negative on days 28-35post-vaccination became sero-positive on day 90. Seven subjects who remained sero-negative during 
days 28-35 and day 90post-vaccination were successfully sero-converted after receiving a second dose 3 months later. Thus, 
two doses of this JE vaccine resulted in a lOO^c (95%c CI, 97.3-100%c) sero-conversion rale with the GMT of 260.8. Eight 
children with GMTs lower than protective level after a single vaccination demonstrated a booster response with GMT of 1237 
after the second dose ofJE vaccination. 
In conclusion, the live attenuated SA14-14-2 vaccine was safe, well tolerated and highly immunogenic with 95%o 
and 100%, sero-conversion rale after one and two doses, respectively. Nevertheless, its long-term immune response and 
possible influences from natural dengue infection requires further evaluation. 
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J a p a n e s e encepha l i t i s ( JE) is the l ead ing 
recognized cause of childhood viral encephalitis in Asia. 
Over 50,000 cases with a case-fatality ratio of 5 - 3 5 % 
are estimated to occur annually in this region" Japan, 
Taiwan and Korea have used an inactivated, mouse 
brain-derived vaccine in their national JE vaccinat ion 
programs and have been successfld in controll ing the 
disease. In other Asian countries, however, the expense 
and complex i ty of p roduc ing the vacc ine wi th the 
Correspondence to: 
Ohrr I!,Department of Preventive Medicine, College of 
Mediciiiclnslilute for Health Promotion, Graduate School of 
Fuhtic Health Yonsei University, Seoul 120-752, Korea. 
Phone: (82-2) 361-5349 
Email: ohrr@yuhs.ac 
requirement of having numerous doses in s tock have 
l imited its implementa t ion . Typically, 2-3 dosee of 
inact ivated mouse brain-der ived vaccine are g iven in 
the primary JE immunization series, followed by booster 
d o s e s to m a i n t a i n immuni ty '^ ' . In a d d i t i o n to the 
l imitat ions posed by mult iple doses , as the vacc ine has 
been introduced e lsewhere to protect t ravelers , a high 
rate o f h y p e r s e n s i t i v i t y e v e n t s has b e e n r e p o r t e d 
a m o n g vaccine recipients in Nor th Amer ica , Europe 
and Austral ia ' '^ ' . 
A l ive-at tenuated JE vaccine m a d e from the 
SA14-14-2 strain was deve loped in China . For m o r e 
than two decades since its l icensing in 1988, this live 
JE vaccine has been safely dis tr ibuted to more than 
100 mil l ion children'^'. T h e vaccine g iven to infants 
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over one year in annual spring campa igns was 9 8 % 
effective when two doses were adminis tered ' ' ' . The 
immunogeni t i c s tudy for K o r e a n chi ldren showed that 
a s ingle p r imary immuniza t ion dose of SA14-14-2 
vaccine produced neutral izing ant ibodies in 9 6 % of 
the subjects and the geometr ic mean titer ( G M T ) was 
188"' \ The efficacy of S A M - 1 4 - 2 vaccine was also 
demonst ra ted in Nepal , as a single dose of SA14-14-2 
vaccine provided 9 8 . 5 % protect ion at one year after 
v a c c i n a t i o n a n d 9 6 . 2 % a t f i v e y e a r s a f t e r 
immunization**^'". Here, w e conducted an open-label 
s t u d y of i m m u n o g e n i c i t y , safety, to le rab i l i ty and 
possible interference in the immune response to a single 
dose of SA14-14-2 vaccine in heal thy Thai infants. 
Material and Method 
Vaccines 
One lot (Lot. No. 200512A085-2) of SAl 4-14-2 
vaccine (CD. J E V A X T M ) produced by the Chengdu 
Institute of Biological Products , Chengdu , China was 
used in the present study. Its respect ive virus titer was 
6 .101ogPFU/0.5ml . 
Study design and procedures 
O n e hundred and fifty healthy Thai infants 
aged 9-15 months recruited at the Queen Sirikit National 
Inst i tute o f Ch i ld Hea l th ( s tudy cen te r ) , Bangkok , 
Thailand, were enrolled in the present study from March 
6 to December 6,2006. Exclusion criteria were as follows: 
had received JE vaccine or any other vaccine within 30 
d a y s b e f o r e e n r o l l m e n t ; k n o w n a l l e r g y to a n y 
componen t of this vaccine; had fever > 37.5°c on day 
of enrol lment ; had received blood or b lood product 
transfusion within 3 mon ths prior enrol lment , had any 
chronic medical illness, immuno compromised condition 
and received systemic steroid therapy; had any medical 
cond i t i on r e su l t ing in p h y s i c i a n ' s ( i n v e s t i g a t o r ' s ) 
decision not to enroll because of a safety reason; and 
known HIV infection. The present study was approved 
by the ethics commit tees (EC) of the study center (EC 
approval No . 82/2548) . Written informed consent was 
obtained from the parents/guardians of all infants before 
enrollment. 
Vaccines were given as 0.5-mL subcutaneous 
injections into the del toid muscle . Part icipants were 
moni tored by s tudy staff for 30 minutes after each 
i n j e c t i o n . P a r e n t s w e r e a s k e d to r e c o r d d a i l y 
temperatures for 7 days , injection site react ions and 
systemic adverse events for 28 days post-vaccinat ion 
in a standardized symptom diary card. Solicited adverse 
events were measu red (fever, erythema, swell ing) and 
categorized as absent, mild, moderate , or severe. Any 
serious adverse events (SAEs) within 28 days after 
e a c h v a c c i n a t i o n w e r e r e c o r d e d and r e p o r t e d 
immediate ly to the investigator. 
Serum samples for JE neutralizing antibody 
were obtained prior to vaccination {Day 0) and 4-5 weeks 
(28-35 days) after vaccinat ion. The JE neutralizing 
ant ibodies were measured through a plaque reduction 
neutralization test (PRNT), 
All par t ic ipants w h o failed to seroconvert 
(as determined by a titer < 1: 10 by J E PRNT test) were 
offered the second dose at 3 months after the first dose. 
C l i n i c a l and i m m u n o g c n c t i c a s s e s s m e n t for the 
subsequent injections was identical to those of the 
first dose . 
Plaque reduction antibody test 
Separated sera were kept under -20°C before 
test ing. The assay was performed according to the 
method descr ibed by Russell et al' The plaque count 
was determined by using LLC-MK^ plaque assay single 
overlay technique. The sera were thawed, diluted and 
heat- inact ivated by incubation at 56°C for 30 minutes. 
Then, serial four-fold dilutions of scrum were made 
( 1 : 10. 1: 4 0 and 1: 160). To contain about 40-50 PEL' 
well , an equal vo lume of diluted JE virus, Beijing anu 
S A l 4 - 1 4 - 2 vaccine strain was added to each serum 
dilut ion tube. Fol lowing incubation at 37°C for 60 
minu tes , 0.2 ml was r emoved from each tube ami 
inoculated onto triplicate 6-well plates of confluent LLC-
MK, . Each plate was incubated at 37°C for 90 minutes 
and monolayers were then overlaid with 4 ml of 3.5*? i. 
Carboxy Methyl Cellulose/MEM. Finally the plates were 
incubated at 37°C with 5 % C O , for 7 days. Plaques 
w e r e c o u n t e d a n d t h e 5 0 % p l a q u e r e d u c t i o n 
neutral izat ion titers (PRNT^,,) were determined. The 
neutra l iza t ion cndpoint in the protocol was a 5 0 % 
reduction in the plaque formation. Antibody titer above 
1:10 was considered posit ive and protect ive ' ' ' 
Data analysis 
T h e se ro -conve r s ion ra te and G M T were 
s u m m a r i z e d w i t h t h e r e s u l t o f P R N T a n d the 
c o r r e s p o n d i n g conf idence interval was calculated 
through an interactive procedure based on the binomial 
p r o b a b i l i t y d i s t r i b u t i o n . T h e p r i m a r y e n d p o i n i 
determinat ion of the present study was the proportion 
of subjects showing sero-conversion for the JE. Sero-
convers ion was defined as a 50 % reduction in the 
P R N T at a > 1: 10 serum dilution (PRNT^J , or a four-
fold increase in the JE neutralizing antibody titer if the 
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subject was JE sero-posit ive prior to vaccinat ion. The 
secondary endpoint tor immunogenic i ty was the G M T 
of JE neutrahzing antibody. In addition, local or general 
adverse events were expressed in percentage as well 
as number for each reaction. SPSS for Windows version 
15.0 (Illinois, Chicago: SPSS Inc, 2006) software was 
used for statistical analysis. 
Results 
The reactogenetic analysis was performed on 
all 150 subjects (males 8 1 , females 69 ; mean age 10.6 
months + 1.7) (Table 1), whereas the immunogene t ic 
a n a l y s i s w a s c o n d u c t e d on 148 s u b j e c t s as t w o 
d ropped out due to family re loca t ion . O f the 148 
s u b j e c t s , 140 s u b j e c t s w e r e s e r o - n e g a t i v e for 
antibodies against JE and dengue ( P R N T for JE and 
d e n g u e a n t i b o d i e s w a s l e s s t h a n 1: 10) b e f o r e 
vaccination. Four subjects had ant ibodies against only 
dengue virus and another four subjects had ant ibodies 
against both JE and dengue viruses before vaccination. 
Reactogenicity 
A 28-day fol low-up for cl inical s igns and 
symptoms showed that the SA14-14-2 vaccine was well 
tolerated. The majority of reported signs and symptoms 
was mild and of short duration. N o serious adverse 
events were vaccine-related, and no parents wi thdrew 
their child from the present study due to a vaccine-
related side effect. Less than 3 % of vaccines reported 
signs and/or symptoms at the injection site. Redness 
was the most frequent local reaction. It would typically 
start on the first day of vaccinat ion and last until one 
day after vaccination, causing no functional l imitation 
of the arm. The most frequently repor ted sys temic 
symptoms were cough (16 .0%), runny nose (10 .7%) 
and low-grade fever (9 .3%), as shown in Tables 2 -1 . Six 
serious adverse events (SAE) occurred during the 2 8 -
day pos t -vacc ina t ion pe r iod . Six cases w h o w e r e 
h o s p i t a l i z e d d u r i n g t h i s p e r i o d i n c l u d e d u p p e r 
respiratory tract infection with acute diarrhea (1). acute 
bronchitis (1), acute asthmatic attack (1), pneumonia 
(2) a n d p h a r y n g i t i s ( 1 ) . A l l o f t h e m r e c o v e r e d 
completely. These SAEs were c o m m o n illnesses in this 
age group and were not considered to be related to 
vaccinat ion. 
A m o n g the eight subjects with dengue pre -
existing ant ibody during pre-vaccinat ion (Day 0), there 
w a s no local r e a c t i o n f o l l o w i n g t h e S A - 1 4 - 1 4 - 2 
vaccinat ion. There was no significant difference of 
systematic reactions, (except for vomit ing) between the 
subjects with dengue ant ibody posi t ive and dengue 
ant ibody negat ive at pre-vaccinat ion (Table 2-2). N o 
subjects with pre-exis t ing d e n g u e an t ibody at p re -
vaccinat ion reported severe s y m p t o m s after the S A -
14-14-2 vaccination. 
Immunogenicity 
General antibody response among 140 pre-
sero-negative (Day 0) for JE and/or Dengue virus 
subjects 
I m m u n o g e n i c i t y w a s e v a l u a t e d o v e r 140 
subjects w h o were sero-negative for JE and/or Dengue 
virus at the beg inn ing of the present study. A total of 
125 subjects demonst ra ted JE sero-convers ion at 2 8 -
35 days after vaccinat ion and 15 subjects did not. The 
sero-conversion rate was 89.3%. (125/140) (95%, CI, 83 .1-
93 .4%) at 28-35 days after vaccinat ion and the G M T 
was 74. However , 8 of the 15 JE sero-negative subjects 
at day 28-35 post-vaccinat ion had demonst ra ted sero-
conversion at 90 days after the first vaccination whereas 
7 subjects remained JE sero-negat ive at 90 days post-
vaccinat ion. The sero-conversion rate for a single dose 
increased to 9 5 % (133/140) (95%, CI, 90.0-97.6%) at 90 
days after the primary vaccination (Fig. 1) and the G M T 
was 66.1 (minimum 11, maximuin 654). These 15 subjects 
had received a second dose 90 days after the first dose . 
Two doses of vacc ine resulted in 100% of JE sero-
conversion ( 9 5 % CI, 97.3-100%,) and the G M T was 260.8 
(minimum 57, maximum 1,034). 
Antibody response after second dose 
Fifteen subjects with JE sero-negat ive at day 
28-35 post-vaccinat ion had received a second dose of 
vaccine 90 days after the first dose . Seven subjects 
Table 1. Demographic characteristics of 150 subjects 
Gender Number of Min age Max age Mean age SD 
subjects (Months) (Months) (Months) 
Male 81 9 15 10.7 1.79 
Female 69 9 14 10.5 1.60 
All 150 9 15 10.6 !.70 
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Table 2-1. Summary of reported clinical adverse events-Day 
(I to 28 post I'^'dose, all 150 subjects 
Adverse Events Day 0-6 
(n = 150) 
No (%) 
Day 7-28 
(n = 150) 
No (%) 
Local reaction 
Redness 4(2.7) 0 (0.0) 
Swelling 3 (2.0) 0 (0.0) 
Induration 2(1.3) 0 (0.0) 
Local pain 2(1.3) 0 (0.0) 
Itching 0 (0.0) 0 (0.0) 
Systemic reaction 
Fever (> 38°C) 14 (9.3) 24(16) 
Eruption 10(6.7) 2(1.3) 
Vomiting 11 (7.3) 15 (10) 
Diarrhea 13 (8.7) 16 (10.7) 
Anorexia 8(5.3) 10 (6.7) 
Cough 24 (16.0) 42 (28.0) 
Fussiness 9 (6.0) 2 (2.3) 
Lethargy 5 (3.3) 2(1.3) 
Convulsion 0 (0.0) 0 (0.0) 
Runny nose 16(10.7) 26(17.3) 
with JE sero-negat ive both at day 28-35 and day 90, 
had demonstrated JE sero-posit ive with G M T of 260.8 
(minimum 57, maximum 1,031) at 4 weeks after the second 
dose (day 120) (Tabic 3, Fig. 1). However, eight subjects 
with JE sero-negat ive at day 30 w h o had JE sero-
posit ive at day 90 , developed a significant secondary 
immune response one month after the second dose of 
the SA-14-14-2 vaccine with G M T markedly increased 
from 66.1 to 1,237 (min imum 164, maximum 16,229) 
{Table 3 , Fig. 1). 
Immune response among different age groups 
N o s ignif icant di f ference in the JE sero-
convers ion rate was observed a m o n g different age 
g roups (Table 4) . It seems that a possible maternal 
ant ibody docs not interfere with the live JE vaccine at 
the age of less than 12 months . 
Immune response among subjects with pre-existing 
dengue virus antibody 
The authors assessed the antibody response 
to live, attenuated JE vaccine among children with pre-
exist ing natural ant ibody against dengue virus. Eight 
TahXe 2-2. Comparison of reported clinical adverse events among dengue naive and pre-existing subjects - Day 0 to 28 post 
P'dose 
Adverse Events Day 0-6 Day 7-28 
Dengue Naive Dengue pre- Dengue Naive Dengue pre-
(n=142) No. (%) existing (n = 142) existing 
antibody No. (%) antibody 
(n = 8) No. (%) (n = 8) No. {%) 
Local reaction 
Redness 4(2.7) 0 0 0 
Swelling 3 (2.0) 0 0 0 
Induration 2(1.3) 0 0 0 
Local pain 2(1.3) 0 0 0 
Itching 0 (0.0) 0 0 0 
Systemic reaction 
Fever (> 3 8 X ) 12(8.5) 2(25) 21 (14.8) 3 (37.5) 
Eruption 10(7.0) 0 (0.0) 2(1.4) 0 (0.0) 
Vomiting 10(7.0) 1 (12.5) 12 (8.5) 3(37.5)-
Diarrhea 12(8.5) 1 (12.5) 14 (9.9) 2 (25.0) 
Anorexia 7(4.9) 1 (12.5) 8(5.7) 2 (25.0) 
Cough 23 (16.2) 1 (12.5) 37 (26.5) 5 (62.5) 
Fussiness 9(6.3) 0 (0.0) 1 (0.7) 1 (12.5) 
Lethargy 5(3.5) 0 (0.0) 2(1.4) 0 (0.0) 
Convulsion 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Runny nose 16(1L3) 0 (0.0) 25 (17.6) 1(12.5) 
a: p < 0.05 
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conversion of JE neutral izing ant ibody with G M T of 
129.2 (minimum 2 1 , maximum 855). Ano the r4 subjects 
with very high titer of pre-exis t ing serotype 2 dengue 
virus ant ibodies had demonst ra ted no secondary JE 
ant ibody response after the SA 14-14-2 single dose 
vaccination (Table 5) . 
Discuss ion 
A live at tenuated S A M - 1 4 - 2 JE vaccine was 
originally developed in China and further characterized 
by a group of US scientists under the auspices of the 
Rockefeller Foundat ion in the early 1990's . It has been 
used nationally in China for the past 17 years. Over 200 
million doses of live attenuated JE vaccine are estimated 
to have been administered so far wi thout any serious 
side effects reported by passive and active surveillance. 
The results of the present study, conducted 
in Bangkok, Thai land, provide evidence to support the 
safety and immunogenic i ty of the live JE vaccine when 
given to healthy Thai infants aged 9-15 months . The 
sero-convers ion rate was 9 5 . 0 % with one dose and 
100% with two doses . This finding is rather similar to 
other clinical or field study results ranging from 8 5 % to 
100% JE sero-conversion rate after one or two doses . 
In a d d i t i o n , it d e m o n s t r a t e d s i m i l a r f i n d i n g s on 
n e u t r a l i z i n g a n t i b o d y r e s p o n s e t o t h e b o o s t e r 
v a c c i n a t i o n wi th a l ive a t t e n u a t e d JE v a c c i n e a s 
repor ted in K o r e a n and N e p a l e s e studies*^'''*. Eight 
Table 3. Neutralizing antibody response of 15 subjects on Day 120 whom had received 2"'' dose on Day 90 
Subjeclcode Day 90PRNT5„ Day 120 PRNT^/ 
SA14-14-2 Gl G2 G3 G4 
001 <10 136 100 27 67 32 
018 <10 57 <10 10 10 <10 
041 <10 150 400 210 208 152 
068 <10 633 29 56 138 36' 
069 <10 105 29 121 105 43 
089 <10 1030 61 29 123 37 
135 <10 1031 169 188 182 52 
005 21 436 302 10 119 89 
Oil 19 164 472 283 340 124 
056 316 1629 1297 4728 2886 1157 
078 17 903 152 524 269 187 
094 24 2726 1295 2816 2745 535 
099 12 1770 362 1331 1061 289 
116 29 1943 542 279 150 131 
146 33 558 154 442 118 96 
subjects w h o had pre-exist ing natural dengue virus 
antibody (D 0) were given one dose of SA 14-14-2 
vaccine. They were included in the safety study, but 
excluded from the immunogenici ty evaluation (Table 
5). All of the 4 subjects with pre-existing naturally-
acquired dengue virus antibody had demonstrated sero-
; so received al Isast ona doaa of JE vaccine ani enWred the rsactogenicity i ludy 
I 2 dropped oul 
- 8 cHMran had pre-eiisting nalural Dengua virus anUbody 
140 entered t^ e Immunoganclty study aftar one dose vaccinalbn 
One doae ot vacdnation at Day 0 
125 were sen^converted at Day ZB-35. 
: Seroconversiwi rate 89.3% (125/140) 
I GMT 74 0 
15 were not BOrroonvertod at Day 26-35 
} were seroconvorlBd Day 90 
: Seroconvarsion rale 95% (133/140) 
: GMT ee i 
7 ramalnad swonagative al Day 90 
. . Second doae vaccinatian at Day 90 h i 
8 ahowad anamnesbc immune raaponBa 
at Day 120 
I Saroconveralon rata 100% (8/8) 
- GMT 1237 
7 wsre serDConvsrled Day 120 
_ saroconvefsran rate 100% (7/7] 
I G M T 260.8 
Fig. I Flow chart of the vaccination and the results of 
seroconversion rate of neutralizing antibody against 
JE virus 
* Plaque reduction neutralizing antibody against Japanese encephalitis serotype 
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Table 4. Seroconversion rate among different age group at day 90 
Age groups Number of subjects SCR* PRNTg^** 
% (n) G M T 
9-11 month 93 95.7(89/93) 118.07 
12-15 month 47 93.6(44/47) 129.63 
Total 140 95.0(133/140) 121.78 
* Seroconversion rate 
** Plaque reduction neutralizing antibody against Japanese encephalitis serotype 
*** No significant difference between 9-11 month and 12-15 month 
Tkble 5. Neutralizing antibody response to a live attenuated JE vaccine among 8 subjects who had pre-existing naturally 
acquired Dengue virus antibody 
Subject code Age (mo) Day JE PRNTjo* 
Dl 
Dengue PRNT,,** 
D2 D3 D4 
002 10 0 <10 2183 59 64 13 
28-35 19 7258 26 116 <10 
1 Y 15 3049 94 19 <!0 
064 10 0 <10 101 219 117 112 
28-35 19 294 189 50 70 
1 Y 748 101 359 72 565 
143 9 0 <10 30 <10 <10 <10 
28-35 14 19 <10 <10 <10 
lY 68 17 <10 <I0 <I0 
050 12 0 <10 77 <10 <10 <10 
28-35 2999 12 <10 <10 <10 
l Y 304 <10 <10 <10 <10 
010 11 0 36 33 1953 38 35 
28-35 10 14 880 19 16 
1 Y 382 79 39130 38 <10 
062 9 0 27 43 1648 84 40 
28-35 15 15 110 10 <10 
1 Y 203 96 75 <10 <10 
072 10 0 23 376 36821 150 45 
28-35 36 326 33573 102 <10 
1 Y 246 52 748 38 67 
091 14 0 25 206 6631 89 49 
28-35 83 97 68652 30 0 
1 Y 1009 239 6412 33208 605 
* Plaque reduction neutralizing antibody against Japanese encephalitis virus serotype 111 
** Plaque reduction neutralizing antibody against Dengue virus serotype (D1-D4) 
s u b j e c t s w h o h a d v a c c i n e - p r i m e d a n t i b o d y 
demons t r a t ed the secondary i m m u n e response of a 
more than four-fold rise (GMT 1237;min 164,max 16229). 
As for the humoral ant ibody response to re-
vaccinat ion with a live a t tenuated vacc ine , the pre-
exist ing ant ibodies in the serum may inhibit a strong 
serologic response to the live at tenuated vaccine, or 
on the other hand, immunological memory may allow 
for a robust serologic response to vaccination*'^*. For 
e x a m p l e , m e a s l e s v a c c i n a t i o n does not boos t the 
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measles antibody titer in an individual with pre-existing 
naturally-acquired and high titer antibody. The immune 
r e s p o n s e o f M M R r e - v a c c i n a t i o n in a d u l t s 
demonstra ted that only subjects with very low and 
undetectable measles ant ibody have a booster effect 
after re-vaccinat ion" '* '* ' . Howeve r , S A 1 4 - 1 4 - 2 re-
vacc ina t ion d e m o n s t r a t e d that eve ry s e c o n d dose 
allowed for a robust boost ing of ant ibody response. 
The excellent safety and protective efficacy 
of the live JE vaccine were acknowledged by the World 
Health Organization"-" and it has been r ecommended 
to JE endemic countries in Asian region by Program for 
Approp r i a t e T e c h n o l o g y in Hea l th (PATH) as an 
alternative to the mouse brain-derived JE vaccine. But 
in Southeast Asian countries where the populat ion is 
suspected to have a high exposure to dengue virus, 
the unsolved quest ion remains whether pre-exis t ing 
ant ibodies to other f laviviruses (i.e. d e n g u e virus) 
interfere with live JE vaccine-induced protection or vice 
versa. 
A rapid onset of broad anamnest ic responses 
was induced with higher-titer heterotypic ant ibodies 
after sequential infection with flavivirus species" ' ' . The 
potential disadvantage caused by ant ibody-dependent 
disease enhancement like secondary infection with 
dengue virus infection could be considered after live 
attenuated JE vaccinat ion. In an animal study, mice 
with sub-neutralizing anti-JEV antibody concentrations 
have been shown to have a high titer of viremia and 
increased morta l i ty after sequential infections wi th 
ano the r flavivirus"'*'. T h e p re sen t s tudy p r o v i d e d 
preliminary data on vaccinat ion a m o n g the subjects 
wi th a pre-ex is t ing an t ibody aga ins t dengue v i rus 
(Table 5). A m o n g 150 subjects, eight were identified 
with a pre-exist ing dengue ant ibody (5 .3%); dengue 
type 2 was the predominant serotype, followed by type 
1, which was generally consistent with the previous 
reports"'^'-"'. Eight subjects, w h o had the pre-exis t ing 
natural dengue virus ant ibody at the initial test, were 
given the SA 14-14-2 JE vaccine. It was well tolerated 
without any serious side effects. No boosting of dengue 
virus antibody titers following the JE vaccinat ion was 
o b s e r v e d . Al l 4 s u b j e c t s w i t h o u t c r o s s - r e a c t i v e 
antibody to the JE virus showed sero-conversion after 
one dose of the SA 14-14-2 vaccine. The G M T was 62.7. 
Another 4 subjects with high pre-existing antibody titer 
to dengue virus serotype 2 showed a possible cross-
reactive ant ibody response to the other serotypes and 
the JE virus. However , further s tudy wi th a larger 
number of subjects should be perfomied to evaluate 
the l o n g - t e r m i m m u n e r e s p o n s e a n d a p o s s i b l e 
influence from natural ly acquired dengue infection. 
In conclus ion, the live a t tenuated SA 14-14-2 
vaccine is safe, general ly wel l tolerated and h ighly 
immunogenic, showing a 9 5 % sero-conversion rate with 
one dose and 100% with two doses in heal thy Thai 
infants aged 9-15 mon ths . 
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m Mivwe/^wwwi as tin^lU, Young Mo Sohn, J Min, Heechoul Ohrr 
iiu^L^-8iilu?iwm4f SA-14-T4-2 Im^nlvimLmuf-^^ i^nfiiy 9-15 m^mimu 150 Imvmftmmuv. 
wnE/QMvjmjQT?^ ej^nifdmrnm-^muQ^^iinurnhf^iL'^^ nuin^mfi seroconversion m ' lnu 95% (95%CI, 
90.0-97.6%) ll&tU^t^UQU^^unv. Geometric Mean Titer (GMT) ivilffu 66.1 li^^'g-j 90 
Qum'imQmumtj'^L^iiL^ii';) i^vL^n 8 m^iyifi'^lmuj^S^nnm^hf^iL'^Q iSfiim 28-35 m-^mii^wui^nm 
iJj 'shfi^i'^Q L^'SQUvl 28-35 'fwu?)r 90 Qii vi^-^t^Qmummi^i.immuuYiijiiun^^iin'um\Q7?i j s a 
m-^tmmm^m^'B^mfit} ^•^uumutif^m'^mL^ui'^S nui^L^QLil'u^iu'ms SA14-14-2 iiimi^o^^uu 2 
i™nun^?i^n^^^W(fwmJn^J 100% (95% CI. 97.3-100%) i.mtmzm GMT 260.8 'BtiiAmimm 8 m rlmt^u 
GMT 1237 
Qmul^f^um^nmui'^^ umiUfiiSumtjrfuf SA14-14-2 umnnilmmm-^ i^nyiwimulm 
m^mi7?^h-5qmmu^-^Q-^ 95% uat 100% nim^A 1 L^^ui^t 2 i^mimi^y 'Bm^hm^mnfmmmt^v 
nif^ni^iMiI'lusiiif^^ 
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